July 12 (Reuters) – Pfizer Inc said on Tuesday the
U.S. Food and Drug Administration had expanded the use of its
best-selling pneumonia vaccine, Prevnar, to adults aged 18
through 49.
The post FDA expands use of Pfizer’s best-selling pneumonia vaccine appeared first on NASDAQ.